[go: up one dir, main page]

UY29766A1 - Formas cristalinas delta y épsilon de mesilato de imatinib - Google Patents

Formas cristalinas delta y épsilon de mesilato de imatinib

Info

Publication number
UY29766A1
UY29766A1 UY29766A UY29766A UY29766A1 UY 29766 A1 UY29766 A1 UY 29766A1 UY 29766 A UY29766 A UY 29766A UY 29766 A UY29766 A UY 29766A UY 29766 A1 UY29766 A1 UY 29766A1
Authority
UY
Uruguay
Prior art keywords
delta
epilon
mesilate
imatinib
crystal shapes
Prior art date
Application number
UY29766A
Other languages
English (en)
Inventor
Michael Mutz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37192362&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY29766(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY29766A1 publication Critical patent/UY29766A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a la forma cristalina delta y épsilon de la sal de adición del ácido metanosulfónico de 4-(4-metilpiperazin-1-ilmetil)-N-(4metil-3-(4-(piridin-3-il)piri-midin-2ilamino)fenil)-benzamida (el compuesto de fórmula I), a ciertos procedimientos para la preparación de las mismas, a composiciones farmacéuticas que contienen a dichas formas cristalinas, y a su utilización en métodos de diagnóstico o para el tratamiento terapéutico de animales de sangre caliente, y a su utulización como compuestos intermedios o para la preparación de preparaciones farmacéuticas para su utilización en métodos de diagnóstico o para el tratamiento terapéutico de animales de sangre caliente, especilmente seres humanos.
UY29766A 2005-08-26 2006-08-24 Formas cristalinas delta y épsilon de mesilato de imatinib UY29766A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71173705P 2005-08-26 2005-08-26
US71173805P 2005-08-26 2005-08-26
US71220605P 2005-08-29 2005-08-29

Publications (1)

Publication Number Publication Date
UY29766A1 true UY29766A1 (es) 2007-03-30

Family

ID=37192362

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29766A UY29766A1 (es) 2005-08-26 2006-08-24 Formas cristalinas delta y épsilon de mesilato de imatinib

Country Status (16)

Country Link
US (1) US7879860B2 (es)
EP (1) EP1922314A1 (es)
JP (1) JP2009506014A (es)
KR (1) KR20080049766A (es)
CN (2) CN102002035B (es)
AR (1) AR055613A1 (es)
AU (1) AU2006283842B2 (es)
BR (1) BRPI0615383A2 (es)
CA (1) CA2620835A1 (es)
EC (1) ECSP088217A (es)
IL (1) IL189353A (es)
MX (1) MX2008002541A (es)
MY (1) MY148375A (es)
NO (1) NO20081482L (es)
UY (1) UY29766A1 (es)
WO (1) WO2007023182A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2824301C (en) * 2005-11-25 2016-01-12 Novartis Ag F, g, h, i and k crystal forms of imatinib mesylate
US7977348B2 (en) 2006-04-27 2011-07-12 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
US8067421B2 (en) 2006-04-27 2011-11-29 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
EP2829538A1 (en) 2006-04-27 2015-01-28 Sicor, Inc. Polymorphic form of imatinib mesylate and process for its preparation
EP2009008A1 (en) 2006-10-26 2008-12-31 Sicor, Inc. Imatinib base, and imatinib mesylate and processes for preparation thereof
US7550591B2 (en) 2007-05-02 2009-06-23 Chemagis Ltd. Imatinib production process
WO2008150481A2 (en) * 2007-05-29 2008-12-11 Sicor Inc. Processes for the preparation of crystalline form beta of imatinib mesylate
EP2081556A1 (en) * 2007-09-25 2009-07-29 Teva Pharmaceutical Industries Ltd. Stable imatinib compositions
US7947699B2 (en) 2008-01-10 2011-05-24 Actavis Group Ptc Ehf Anhydrous amorphous imatinib mesylate
US20100330130A1 (en) 2009-05-22 2010-12-30 Actavis Group Ptc Ehf Substantially pure imatinib or a pharmaceutically acceptable salt thereof
CZ2009570A3 (cs) 2009-08-26 2011-03-09 Zentiva, K. S. Príprava, stabilizace a využití polymorfu imatinib mesylátu pro vývoj lékových forem
PL389357A1 (pl) 2009-10-22 2011-04-26 Tomasz Koźluk Sole imatinibu z pochodnymi kwasów winowych i sposób ich wytwarzania
WO2011095835A1 (en) 2010-02-02 2011-08-11 Actavis Group Ptc Ehf Highly pure imatinib or a pharmaceutically acceptable salt thereof
EP2536707A1 (en) 2010-02-15 2012-12-26 Reliance Life Sciences Pvt., Ltd. Process for the preparation of alpha form of imatinib mesylate
PL390611A1 (pl) 2010-03-04 2011-09-12 Tomasz Koźluk Sposób otrzymywania polimorficznej formy alfa i nowa forma polimorficzna mesylanu imatinibu
WO2011157450A1 (en) 2010-06-18 2011-12-22 Krka, D. D., Novo Mesto New polymorphic form of imatinib base and preparation of salts thereof
CN102477031B (zh) 2010-11-30 2015-07-15 浙江九洲药业股份有限公司 一种甲磺酸伊马替尼α晶型的制备方法
WO2012090221A1 (en) 2010-12-29 2012-07-05 Cadila Healthcare Limited Novel salts of imatinib
PL394169A1 (pl) 2011-03-09 2012-09-10 Adamed Spółka Z Ograniczoną Odpowiedzialnością Kompozycja farmaceutyczna metanosulfonianu imatinibu do napełniania jednostkowych postaci dawkowania oraz sposób jej wytwarzania
EP2604596A1 (en) * 2011-12-16 2013-06-19 Deva Holding Anonim Sirketi Polymorphs of imatinib
JP5928159B2 (ja) * 2012-05-28 2016-06-01 ニプロ株式会社 医薬組成物
CA2877030A1 (en) 2012-06-22 2013-12-27 Basf Se Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers
CN105560246B (zh) * 2012-08-04 2019-07-26 正大天晴药业集团南京顺欣制药有限公司 甲磺酸伊马替尼α结晶的制备及其药物组合物
ES2683361T3 (es) 2013-05-14 2018-09-26 Hetero Research Foundation Composiciones de Imatinib
WO2017078647A1 (en) 2015-11-05 2017-05-11 Koçak Farma Ilaç Ve Kimya Sanayi Anonim Şirketi Pharmaceutical compositions of imatinib
EP3407874B1 (en) 2016-01-25 2024-05-22 KRKA, d.d., Novo mesto Fast dispersible pharmaceutical composition comprising tyrosine-kinase inhibitor
PL3539138T3 (pl) 2016-11-11 2021-12-13 Curium Us Llc Sposoby generowania germanu-68 ze zmniejszoną ilością części lotnych
CN112851640B (zh) * 2019-11-28 2023-09-01 广东东阳光药业股份有限公司 嘧啶苯甲酰胺化合物的硫酸盐及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US7300938B2 (en) 2003-06-02 2007-11-27 Hetero Drugs Limited Polymorphs of imatinib mesylate
ES2565078T3 (es) * 2004-02-11 2016-03-31 Natco Pharma Limited Forma polimorfa novedosa de mesilato de imatinib y un proceso para su preparación
UA84462C2 (ru) 2004-04-02 2008-10-27 Институт Фармацевтични Полиморфные модификации кислотно-аддитивных солей иматиниба с метансульфоновой кислотой
KR101348625B1 (ko) * 2004-09-02 2014-01-07 씨아이피엘에이 엘티디. 이매티닙 메실레이트의 안정한 결정형 및 그의 제조방법
WO2006048890A1 (en) * 2004-11-04 2006-05-11 Sun Pharmaceutical Industries Limited Imatinib mesylate crystal form and process for preparation thereof
WO2006054314A1 (en) 2004-11-17 2006-05-26 Natco Pharma Limited Polymorphic forms of imatinib mesylate

Also Published As

Publication number Publication date
JP2009506014A (ja) 2009-02-12
MX2008002541A (es) 2008-03-14
AU2006283842A1 (en) 2007-03-01
IL189353A0 (en) 2008-06-05
US20080254116A1 (en) 2008-10-16
IL189353A (en) 2014-12-31
BRPI0615383A2 (pt) 2011-05-17
NO20081482L (no) 2008-05-16
ECSP088217A (es) 2008-03-26
AU2006283842B2 (en) 2011-03-17
CN101243066B (zh) 2012-11-14
WO2007023182A1 (en) 2007-03-01
EP1922314A1 (en) 2008-05-21
AR055613A1 (es) 2007-08-29
CN102002035B (zh) 2013-02-27
CN101243066A (zh) 2008-08-13
US7879860B2 (en) 2011-02-01
MY148375A (en) 2013-04-15
KR20080049766A (ko) 2008-06-04
CA2620835A1 (en) 2007-03-01
CN102002035A (zh) 2011-04-06

Similar Documents

Publication Publication Date Title
UY29766A1 (es) Formas cristalinas delta y épsilon de mesilato de imatinib
UY31125A1 (es) Formas amorfas estabilizadas de mesilato de imatinib
ECSP088473A (es) FORMAS DE CRISTAL F, G, H, I, y K DEL MESILATO DE IMATINIB
AR078766A1 (es) Formas solidas de n-(4-(7-azabiciclo(2.2.1) heptan-7-il)-2-( trifluorometil) fenil)-4-oxo-5-(trifluorometil)-1,4- dihidroquinolina-3-carboxamida
CO6150162A2 (es) Pirrolopirimidinas para composiciones farmaceuticas
CR11554A (es) Pirrolo-Pirimidinas y Pirrolo-Piridinas
AR064256A1 (es) Sales y formas de cristal del 2-metil-2-[4-(3-metil-2-oxo-8-quinolin-3-il-2,3-dihidro-imidazo-[4,5-c] -quinolin-1-il)-fenil] -propionitrilo
CY1118340T1 (el) Αναστολεις κινασης
CR20120002A (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos
ECSP066383A (es) Derivados de 5-fenil-4-metil-tiazol-2-il-amina como inhibidores de enzimas de cinasa fosfatidilinositol 3 (pi3) para el tratamiento de enfermedades inflamatorias de las vías respiratorias
DK1826197T3 (da) Aminocarboxylsyrederivater og medicinsk anvendelse deraf
ECSP088210A (es) Bencimidazoles sustituidos y métodos de preparación
UY30641A1 (es) Derivados de 2-[1h-pirazol-5-il] y de 2-[2h-pirazol-3-il]tieno[3,2-c]piridinas sustituidas, sus sales farmaceuticamente aceptables y aplicaciones
DOP2012000153A (es) Derivados de sulfonamida como agentes inductores de apoptosis con selectividad por bcl-2 para el tratamiento de cancer y enfermedades inmunes
UY29633A1 (es) Derivados de oxindol
UA109290C2 (uk) Спільні кристали і солі інгібіторів ccr3
AR053554A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
BRPI0921595B8 (pt) sal monocloridrato cristalino de 4-[2,4,6-(trifluorfenoximetil)fenil]piperidina, seu processo de preparo e usos
ECSP10010150A (es) Forma cristalina 1 de 2-(r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida
AR054779A1 (es) N-(2,2-dimetilpropil)-6-{3-fluoro-5-[(3-isoxazolilamino)carbonil]-2-metilfenil}-3-piridinacarboxamida
DOP2012000056A (es) Agente terapeutico para trastornos de ansiedad
ECSP099082A (es) Beta-agonistas enantioméricamente puros, procedimientos para su preparación y su uso como medicamentos
UY29394A1 (es) Derivados sustituidos de n-(5-(2-propilamino.1.hidroxietil)-2-hdroxifenil) metano sulfonamida, composiciones farmacéuticas que lo contienen y aplicaciónes.
UY30029A1 (es) Derivados de piperidina, sus sales farmacéuticamente aceptables, composiciones farmacéuticas conteniéndolos y aplicaciones
ATE440836T1 (de) Verbindungen

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20161111